Tocilizumab en artritis reumatoideTocilizumab in rheumatoid arthritis

https://doi.org/10.1016/j.reuma.2011.01.001Get rights and content

Resumen

Tocilizumab (TCZ) es un anticuerpo monoclonal humanizado dirigido contra el receptor de la IL-6, aprobado para el tratamiento de la artritis reumatoide (AR) en Japón, Europa y EE. UU. Un amplio desarrollo clínico ha demostrado la eficacia del TCZ en la mayoría de las situaciones posibles de la AR: AR sin fallo previo a MTX (AMBITION), AR refractaria a MTX (SATORI, OPTION, LITHE) o a cualquier fármaco modificador de la enfermedad (TOWARD, ROSE), así como AR refractaria a agentes anti-factor de necrosis tumoral alfa (RADIATE). Además de su inicio precoz, esta eficacia se mantiene constante e incluso aumenta con el paso del tiempo (GROWTH95, GROWTH96). TCZ ha demostrado gran eficacia en la corrección de las alteraciones analíticas de la AR, tanto en los reactantes de fase aguda como en la anemia de trastorno inflamatorio. Aunque en la AR el TCZ está indicado inicialmente en combinación con MTX, también ha sido demostrada su eficacia en monoterapia (AMBITION). TCZ es igualmente eficaz en la prevención del daño estructural (SAMURAI, LITHE). Además, TCZ ha demostrado ser un fármaco seguro y bien tolerado, similar a otras terapias biológicas. Todos estos datos hacen del TCZ una alternativa terapéutica adecuada a tener en cuenta en cualquier escenario de la AR.

Abstract

Tocilizumab (TCZ) is a humanized monoclonal antibody directed against the receptor for IL-6, approved for the treatment of rheumatoid arthritis (RA) in Japan, Europe and the US. Wide clinical development has shown the efficacy of TCZ in most of the possible situations of RA: RA without prior failure to MTX (AMBITION), RA unresponsive to MTX (SATORI, OPTION, LITHE) or any DMARD (TOWARD, ROSE) as well as RA refractory to anti-TNFa agents (RADIATE). In addition to its early onset, efficacy was constant and even increased as time passed (GROWTH95, GROWTH96). TCZ has shown great efficacy in correcting laboratory alterations in RA, both in acute phase reactants as well as anemia of inflammatory disease. Although in RA TCZ us initially indicated in combination with MTX, it has also shown its efficacy as monotherapy (AMBITION). TCZ is equally effective in the prevention of structural damage (SAMURAI, LITHE). In addition, it has shown to be a safe and well-tolerated drug, similar to other biologic therapies. All of these aspects make TCZ an adequate therapeutic alternative to be considered in any RA scenario.

Section snippets

Conflicto de intereses

Los autores declaran no tener ningún conflicto de intereses.

Bibliografía (15)

  • J.L. Pablos Álvarez

    La interleucina 6 en la fisiopatología de la artrirtis reumatoide

    Reumatol Clin.

    (2009)
  • R.N. Maini et al.

    Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

    Arthritis Rheum.

    (2006)
  • N. Nishimoto et al.

    Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

    Mod Rheumatol.

    (2009)
  • N. Nishimoto et al.

    Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI). Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab

    Ann Rheum Dis.

    (2007)
  • J.S. Smolen et al.

    Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial

    Lancet.

    (2008)
  • J.M. Kremer et al.

    Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: The LITHE study

    Arthritis Rheum.

    (2008)
  • M.C. Genovese et al.

    Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therpy study

    Arthritis Rheum.

    (2008)
There are more references available in the full text version of this article.

Cited by (0)

View full text